Venturi Wealth Management LLC Invests $92,000 in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Venturi Wealth Management LLC bought a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 2,534 shares of the specialty pharmaceutical company’s stock, valued at approximately $92,000.

Other institutional investors have also bought and sold shares of the company. Stephens Investment Management Group LLC lifted its position in shares of Supernus Pharmaceuticals by 1.8% during the third quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock valued at $60,246,000 after purchasing an additional 33,710 shares in the last quarter. Pacer Advisors Inc. increased its stake in Supernus Pharmaceuticals by 29.9% in the 3rd quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock valued at $54,655,000 after buying an additional 403,028 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Supernus Pharmaceuticals by 5.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after buying an additional 74,438 shares in the last quarter. Victory Capital Management Inc. boosted its stake in shares of Supernus Pharmaceuticals by 1.1% in the 3rd quarter. Victory Capital Management Inc. now owns 742,871 shares of the specialty pharmaceutical company’s stock worth $23,163,000 after buying an additional 7,833 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Supernus Pharmaceuticals by 14.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 712,395 shares of the specialty pharmaceutical company’s stock valued at $22,212,000 after acquiring an additional 91,354 shares in the last quarter.

Insiders Place Their Bets

In related news, VP Padmanabh P. Bhatt sold 700 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total value of $27,734.00. Following the sale, the vice president now owns 10,149 shares in the company, valued at approximately $402,103.38. This trade represents a 6.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 9.30% of the stock is owned by corporate insiders.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock opened at $33.05 on Monday. The stock has a market capitalization of $1.82 billion, a P/E ratio of 30.89 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $40.28. The stock’s 50-day simple moving average is $37.48 and its 200 day simple moving average is $35.38.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald downgraded Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $57.00 to $36.00 in a research note on Wednesday, February 19th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.